We evaluated the activity in terms of time to progression (TTP) of mitomycin C and capecitabine in patients with advanced colorectal cancer who progressed after 2 lines of chemotherapy.
Methods
Patients with advanced colorectal cancer undergoing third-line chemotherapy after failure of 5-FU with CPT-11 or oxaliplatin-based chemotherapy regimens were treated with capecitabine and mitomycin C.
Results
Sixty-one patients were enrolled in this study. The median age was 55 years (range, 26-78 years) and the male:female ratio 21: 40. We observed partial remissions in 5 patients (8%), stable disease in 25 patients (40%) and progression of disease in 31 patients (52%). Median TTP was 3 months and median survival was 6 months. Global toxicity was mild and entirely acceptable. Grade 3-4 hematological toxicity occurred in 12 patients and grade 3-4 nonhematological toxicity in 5 patients.
Conclusions
The combination of capecitabine and mitomycin C could represent an effective and manageable treatment option for colorectal cancer patients failing previous chemotherapy regimens.
De GramontA., FigerA., SeymourM., HomerinM., HmissiA., CassidyJ., BoniC., Cortes-FunesH., CervantesA., FreyerG., PapamichaelD., Le BailN., LouvetC., HendlerD., de BraudF., WilsonC., MorvanF., BonettiA.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol,18: 2938–2947, 2000.
2.
DouillardJ.Y., CunninghamD., RothA.D., NavarroM., JamesR.D., KarasekP., JandikP., IvesonT., CarmichaelJ., AlakiM., GruiaG., AwadL., RougierP.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.Lancet,355: 1041–1047, 2000.
3.
RougierP., LepilleD., BennounaJ., MarreA., DucreuxM., MignotL., HuaA., Mery-MignardD.: Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicenter phase II study.Ann Oncol,13: 1558–1567, 2000.
4.
SaltzL.B., CoxJ.V., BlankeC., BlankeC., RosenL.S., FehrenbacherL., MooreM.J., MarounJ.A., AcklandS.P., LockerP.K., PirottaN., ElfringG.L., MillerL.L.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med,343: 905–914, 2000.
5.
MiwaM., UraM., NishidaM., SawadaN., IshikawaT., MoriK., ShimmaN., UmedaI., IshitsukaH.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.Eur J Cancer,34: 1274–1281, 1998.
6.
SchullerJ., CassidyJ., DumontE., RoosB., DurstonS., BankenL., UtohM., MoriK., WeidekammE., ReignerB.: Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients.Cancer Chemother Pharmacol,45: 291–297, 2000.
7.
HoffP.M., AnsariR., BatistG., CoxJ., KochaW., KupermincM., MarounJ., WaldeD., WeaverC., HarrisonE., BurgerH.U., OsterwalderB., WongA.O., WongR.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.J Clin Oncol,19: 2282–2292, 2001.
8.
CassidyJ., TwelvesC., Van CutsemE., HoffP., BajettaE., BoyerM., BugatR., BurgerU., GarinA., GraevenU., McKendrickJ., MarounJ., MarshallJ., OsterwalderB., Perez-MangaG., RossoR., RougierP., SchilskyR.L.: First line oral capecitabine therapy in metastatic colorectal cancer, a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.Ann Oncol,13: 566–575, 2002.
9.
TwelvesC.Xeloda Colorectal Cancer Group: Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.Eur J Cancer,38: 15–20, 2002.
10.
Van CutsemE., TwelvesC., CassidyJ., AllmanD., BajettaE., BoyerM., BugatR., FindlayM., FringsS., JahnM., McKendrickJ., OsterwalderB., Perez-MangaG., RossoR., RougierP., SchmiegelW.H., SeitzJ.F., ThompsonP., VieitezJ.M., WeitzelC., HarperP.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer, results of a large phase III study.J Clin Oncol,19: 4097–4106, 2001.
11.
CassidyJ., TaberneroJ., TwelvesC., BrunetR., ButtsC., ConroyT., DebraudF., FigerA., GrossmannJ., SawadaN., Schoffs-kiP., SobreroA., Van CutsemE., Diaz-RubioE.: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.J Clin Oncol,22: 2084–2091, 2004.
12.
PattY., LiebmannJ., DiamandidisD., EckhardtG., JavleM., JusticeG., KeiserL.W., LeeF.C., MillerW., LinE.: Final efficacy and safety findings from a phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC).Ann Oncol,15: iii8 (abstr 328), 2004.
13.
RaoS., CunninghamD., PriceT., HillM.E., RossP.J., TebbuttN., NormanA.R., OatesJ., ShellitoP.: Phase II study of capecitabine and mitomycin C as first line treatment in patients with advanced colerectal cancer.Br J Cancer,91: 839943, 2004.
14.
CaoS., LuK., IshitsukaH., RustumY.M.: Antitumor efficacy of capecitabine against fluorouracil-sensitive and resistant tumors (Meeting abstract).Proc Am Soc Clin Oncol,16: 226 (abstr 795), 1997.
15.
IshikawaT., UtohM., SawadaN., NishidaM., FukaseY., SekiguchiF., IshitsukaH.: Tumour selective delivery of 5 fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.Biochem Pharmacol,55: 1091–1097, 1998.
16.
IschitsukaH.: Capecitabine, preclinical pharmacology studies.Invest New Drugs,18: 343–354, 2000.
17.
SawadaN., IshikawaT., FukaseY., NishidaM., YoshikuboT., IshitsukaH.: Induction of thymidine Phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.Clin Cancer Res,4: 1013–1019, 1998.
18.
YamashitaK., MikamiY., HirabayashiY., IkedaM., FujikuraH., OkaY., YoshidaK., IwamotoS., KimotoM., TsunodaT.: Induction of thymidine Phosphorylase (TP) and dihydropyrimi-dine dehydrogenase (DPD) activity and influence of the capecitabine efficacy of mitomycin C (MMC) in human colorectal cancer (CC), final results.Proc ASCO,21: 145 (abstr 2394), 2002.
19.
ChesterJ.D., DentJ.T., WilsonG., RideE., SeymourM.T.: Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer.Ann Oncol,11: 135–137, 2000.
20.
RossP., NormanA., CunninghamD., WebbA., IvesonT., PadhaniA., PrendvilleJ., WatsonM., MasseyA., PopescuR., OatesJ.: A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.Ann Oncol,8: 995–1001, 1997.
21.
TherasseP., ArbuckS.G., EisenhauerE.A., WandersJ., KaplanR.S., RubinsteinL., VerweijJ., Van GlabbekeM., van OosteromA.T., ChristianM.C., GwytherS.G.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.J Natl Cancer Inst,92: 205–216, 2000.
22.
SimonR., WittesR.E.: Methodologic guidelines for reports of clinical trials.Cancer Treat Rep,69: 1–3, 1985.
23.
ChauI., WebbA., CunninghamD., HillM., WatersJ.S., NormanA., MasseyA.: Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.Br J Cancer,85: 1258–1264, 2001.
24.
SastreJ., AlfonsoR., MaciasJ.A., ManriqueI., FloresL., Diaz-RubioE.: E 5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimen as first line.Anticancer Drugs,14: 543–547, 2003.
25.
AndreT., Lou vetC., Maindrault-GoebelF., CouteauC., MabroM., LotzJ.P., Gilles-AmarV., KrulikM., CarolaE., IzraelV., de GramontA.: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer.GERCOR. Eur J Cancer,35: 1343–1347, 1999.
26.
RothenbergM.L., OzaA.M., BigelowR.H., BerlinJ.D., MarshallJ.L., RamanathanR.K., HartL.L., GuptaS., GarayC.A., BurgerB.G., Le BailN., HallerD.G.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.J Clin Oncol,1: 2059–2069, 2003.
27.
Van CutsemE., BlijhamG.H.: Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.Semin Oncol,26: 6–12, 1999.
28.
AndreT., BensmaineM.A., LouvetC., FrancoisE., LucasV., DesseigneF., BeerblockK., BoucheO., CarolaE., MerroucheY., MorvanF., Dupont-AndreG., de GramontA.: Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.J Clin Oncol,11: 3560–3568, 1999.
29.
BamiasA., PapamichaelD., SyrigosK., PavlidisN.: Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pre-treated patients with advanced colorectal and gastric cancer.J Chemother,15: 275–281, 2003.
30.
BrienzaS., BensmaineM.A., SouliéP., LouvetC., GamelinE., FrancoisE., DucreuxM., MartyM., AndréT., de BraudF., BleibergH., SegalV., ItzhakiM., CvitkovicE.: Oxaliplatin added to 5-fluorouracil-based therapy (5-FU+/-FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.Ann Oncol,10: 1311–1316, 1999.
31.
CunninghamH., HumbletY., SienaS., KhayatD., BleibergH., SantoroA., BetsD., MueserM., HarstickA., VerslypeC., ChauI., van CutsemE.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med,351: 337–345, 2004.
